Abstract
Scolopendra subspinipes mutilans, also known as Chinese red-headed centipede, is a venomous centipede from East Asia and Australasia. In traditional Chinese medicine, this centipede has been widely used for the treatment of various ailments, but few researches on the venom from this centipede have been conducted so far. In the present study, we reported that the venom could potently suppress the growth of the myelogenous leukemia cell lines K562, U937 and HL- 60, in a dose-dependent manner with IC50 values of 20 μg/mL, 30 μg/mL, 200 μg/mL, respectively. K562 cells treated with the venom showed typical morphological indicators of apoptosis including condensation of nuclei. Annexin V-FITC and propidium iodide double staining further demonstrated that the venom had potent apoptogenic activity. Venom treatment induced caspase 2, 3, 6, 8 and 9 activation in K562 cells, which might involve in the venom-induced apoptosis. The venom could also cause cell cycle arrest. Increased cell accumulation at S phase was observed in K562 cells treated with the venom. Taken together, the Chinese red-headed centipede venom could inhibit the growth of myelogenous leukemia cell lines through apoptosis induction and cell cycle arrest. It might be a useful source for the identification of substances with anti-leukemia activity.
Keywords: Centipede, Scolopendra subspinipes mutilans, Venom, Myelogenous leukemia cell line, Cell growth inhibition
Letters in Drug Design & Discovery
Title:The Venom of the Centipede Scolopendra subspinipes mutilans Inhibits the Growth of Myelogenous Leukemia Cell Lines
Volume: 10 Issue: 5
Author(s): Shiyan Xu, Fan Zhang, Hengyun Wang, Yu Liu, Dan Li, Zhe Wu and Zhonghua Liu
Affiliation:
Keywords: Centipede, Scolopendra subspinipes mutilans, Venom, Myelogenous leukemia cell line, Cell growth inhibition
Abstract: Scolopendra subspinipes mutilans, also known as Chinese red-headed centipede, is a venomous centipede from East Asia and Australasia. In traditional Chinese medicine, this centipede has been widely used for the treatment of various ailments, but few researches on the venom from this centipede have been conducted so far. In the present study, we reported that the venom could potently suppress the growth of the myelogenous leukemia cell lines K562, U937 and HL- 60, in a dose-dependent manner with IC50 values of 20 μg/mL, 30 μg/mL, 200 μg/mL, respectively. K562 cells treated with the venom showed typical morphological indicators of apoptosis including condensation of nuclei. Annexin V-FITC and propidium iodide double staining further demonstrated that the venom had potent apoptogenic activity. Venom treatment induced caspase 2, 3, 6, 8 and 9 activation in K562 cells, which might involve in the venom-induced apoptosis. The venom could also cause cell cycle arrest. Increased cell accumulation at S phase was observed in K562 cells treated with the venom. Taken together, the Chinese red-headed centipede venom could inhibit the growth of myelogenous leukemia cell lines through apoptosis induction and cell cycle arrest. It might be a useful source for the identification of substances with anti-leukemia activity.
Export Options
About this article
Cite this article as:
Xu Shiyan, Zhang Fan, Wang Hengyun, Liu Yu, Li Dan, Wu Zhe and Liu Zhonghua, The Venom of the Centipede Scolopendra subspinipes mutilans Inhibits the Growth of Myelogenous Leukemia Cell Lines, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050004
DOI https://dx.doi.org/10.2174/1570180811310050004 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Chrysin Induces Apoptosis in Peripheral Blood Lymphocytes Isolated from Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Kinase Inhibitor Conjugates
Current Pharmaceutical Design Bioactive Natural Compounds from the Mangrove Endophytic Fungi
Mini-Reviews in Medicinal Chemistry Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Current Pharmaceutical Design Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery
Current Drug Targets Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued)